Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

NCT03381274 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL: Oleclumab
DRUG: Osimertinib
DRUG: AZD4635

Sponsor

MedImmune LLC